- Pediatrics (Journal of the American Academy of Pediatrics) has published a paper on the first two children treated with Mesoblast’s (NASDAQ:MESO) mesenchymal stromal cell (MSC) product candidate remestemcel-L for multisystem inflammatory syndrome (MIS-C) associated with COVID-19.
- The two patients detailed in the paper were previously exposed to COVID-19 infection and later developed MIS-C.
- When treated with two intravenous doses of remestemcel-L separated by 48 hours, normalization of left ventricular ejection fraction, notable reductions in biomarkers of systemic and cardiac inflammation, and improved clinical status occurred.
- There were no safety signals associated with the remestemcel-L treatment. Both patients were discharged from hospital.
- Remestemcel-L exhibits beneficial effects relative to the cardiac and vascular pathophysiology associated with this inflammatory disease state in children. This therapy holds promise as a novel treatment for MIS-C.
- Shares up 15% premarket.